Event > Conference >
The World Congress on Alternatives and Animal Use in the Life Sciences
CN Bio CSO Dr. Kostrzewski will be presenting at The World Congress on Alternatives and Animal Use in the Life Sciences (WC13-2025) Rio de Janeiro.
We’re excited to present at The World Congress on Alternatives and Animal Use in the Life Sciences (WC13-2025): 3Rs Integrating 3 worlds – Human, Animal and Environmental Health
WC13 is a significant international event that focuses on advancing the field of alternatives to animal testing in research and education.
Our presentations:
Title: Collaborative approaches to build confidence in the application of microphysiological systems
Session: 101: Formulating a framework for non-animal safety assessment of human pharmaceuticals
Date: 3 September 2025, Wednesday
Time: 11:30 -13:00
Venue: Plenary Room
Presenter: Dr. Tomasz Kostrzewski
Title: Building Confidence in MPS Use in Regulatory Applications: The 3Rs Collaborative’s & FDA-CDER’s Cross-Platform DILI Project
Session: 133: Innovations in Microphysiological Systems: Advancing translational research and regulatory risk assessment
Date: 4th September 2025, Thursday
Time: 09:30 -11:00
Venue: Room 201
Presenter: Dr. Tomasz Kostrzewski
Meet the team at WC 13
Tomasz
Dr. Tomasz Kostrzewski has more than 15 years of experience in molecular and cellular biology research. He joined CN Bio in 2015 and was promoted to Director of Biology in 2018 with responsibility for biological model development and collaborative research projects with academia, pharma, and regulators. In 2021 he was promoted to VP of Science and Technology and then to Chief Scientific Officer in 2023, with responsibility for all technical activities, including developing new products, technologies, and assays, as well as contract research services. Dr Kostrzewski has managed multiple grant-funded collaborative projects at CN Bio and is currently the project lead for the collaborative project between CN Bio and the FDA. He has published more than twelve peer-reviewed scientific articles in the last five years and submitted several patent applications. Prior to joining CN Bio, he worked at Imperial College London in the Department of Life Sciences studying immune cell development and stem cell differentiation, as well as at GlaxoSmithKline working in biopharmaceutical drug discovery and development. Dr Kostrzewski holds three degrees from the University of Sheffield and Imperial College London in Cell and Molecular Biology.